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Abstract
Background and Purpose
Epoxyeicosatrienoic acids (EETs) are arachidonic acid metabolites that play a protective
role against damaging processes that may occur after re-oxygenation of the graft. We
aimed to investigate whether the presence of functional polymorphisms in the gene encod-
ing soluble epoxy hydrolase (EPHX2), which metabolizes EETs to less active compounds,
may play a role in the outcome of renal transplantation.
Methods
In a group of 259 Caucasian renal transplant recipients and 183 deceased donors, we
determined the presence of three common EPHX2 SNPs, namely rs41507953 (K55R),
rs751141 (R287Q) and rs1042032 A/G. Associations with parameters of graft function and
the incidence of acute rejection were retrospectively investigated throughout the first year
after grafting by logistic regression adjusting for clinical and demographic variables.
Results
Carriers of the rs1042032 GG genotype displayed significantly lower estimated glomerular
filtration rate (eGFR) (38.15 ± 15.57 vs. 45.99 ± 16.05; p = 0.04) and higher serum creatinine
values (1.57 ± 0.58 vs. 1.30 ± 0.47 g/dL; p=0.02) one year after grafting, compared to
patients carrying the wildtype A-allele. The same GG genotype was also associated to
increased risk of acute rejection. Interestingly, this association was observed for the geno-
type of both recipients [OR =6.34 (1.35-29.90); p = 0.015] and donors [OR = 5.53 (1.10-
27.80); p=0.042]. A statistical model including both genotypes along with other meaningful
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demographic and clinical variables resulted in an increased significance for the association
with the recipients’ genotype [OR=8.28 (1.21-74.27); p=0.031].
Conclusions
Our results suggest that genetic variability in the EETs-metabolizing gene, EPHX2, may
have a significant impact on the outcome of deceased-donor renal transplantation.
Introduction
The arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to a number of
compounds with important biological functions. The epoxygenase branch of this pathway
leads to the synthesis of epoxyeicosatrienoic acids (EETs), which are considered to be endothe-
lium-derived hyperpolarizing factors that regulate the intracellular transport of electrolytes
and maintain vascular smooth muscle tone with vasodilator and anti-inflammatory properties
[1–3]. In turn, EETs are metabolized to less active dihydroxyeicosatrienoic acids (DHETs) by
soluble epoxide hydrolase (sEH) [4].
There presently is an increasing body of evidence suggesting that these EETs may have a sig-
nificant function in organ transplantation. Thus, these compounds have been shown to play a
protective role in the kidney [5,6], particularly against damaging processes that may occur after
re-oxygenation of the graft [7–9]. Indeed, increasing the levels of EETs, via sEH inhibition, has
been proposed as a therapeutic strategy in renal diseases [2].
The EET-metabolizing enzyme sEH is encoded by the EPHX2 gene, which is expressed in
the kidney and presents single nucleotide polymorphisms (SNPs) that have been associated
with altered enzyme activity [10,11]. Previous disease-association studies have shown that cer-
tain genetic variations in EPHX2 are related to the risk of coronary heart disease and ischemic
stroke [12,13]. In addition, one recent study in rodents has reported that sEH activity deter-
mines the severity of ischemia-reperfusion injury in the kidney [14]. To our knowledge, only
two studies by the same research group have analyzed the impact of EPHX2 genetic variability
on kidney disease and transplantation. The authors showed that some of these variants can
affect the progression of human IgA nephropathy and may be predictive of allograft dysfunc-
tion, but no assessment was made on their impact on acute rejection [15,16].
With this background, we hypothesize that the presence of polymorphisms with an estab-
lished functional and/or clinical relevance in the EPHX2 gene, namely rs41507953 (K55R),
rs751141 (R287Q) and rs1042032 in the 3’ untranslated region (UTR), may play a role in the
outcome of renal transplantation. To test this hypothesis, we retrospectively analyzed these
variants in a population of renal transplant recipients and donors and searched for associations
with graft dysfunction and acute rejection episodes (ARE).
Subjects and Methods
From an initial number of 354 clinical records reviewed, a total of 259 adult renal transplant
recipients were included in the final study sample (patients with incomplete records of clinical
parameters, demographic characteristics or those with failed genotyping were ruled out from
the study). Part of these patients had already been studied in previous works by our group [17–
19]. The patients were all of Caucasian origin and received a single kidney at two Spanish cen-
ters, the Infanta Cristina Hospital in Badajoz and the Hospital Universitario Central de
EPHX2 Polymorphisms in Renal Transplant
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Asturias in Oviedo. All transplants were carried out with deceased donors from whom genetic
material was available in 183 cases.
After the transplant, a triple immunosuppressive therapy was implemented with mycophe-
nolate mofetil (2 g/day), a tapering schedule of corticoids (500 mg IV methylprednisolone at
the time of surgery, 125 mg intravenously (IV) the following day and then 20 mg of oral pred-
nisone daily, progressively tapered to 5 mg daily at 2 months after transplantation) and either
cyclosporine or tacrolimus. Tacrolimus starting dose was set to 0.1 mg/kg administered twice a
day. Initial dosage of Cyclosporine was 4–10 mg/kg/day divided into two administrations. The
first dose was administered orally shortly before transplantation or IV in the perioperative
period when the patient's condition did not support the enteral route. The amount of drug
administered IV was one third of the oral dose. Further doses of immunosupressants were sub-
sequently adjusted according to blood concentrations. Tacrolimus and cyclosporine blood con-
centrations were routinely measured using an immunoassay performed on a Cobas Mira Plus
analyzer (Roche Diagnostics).
Acute allograft rejection was established by histological findings in renal biopsies according
to the Banff classification and/or by clinical evaluation as previously described [18,20]. Delayed
graft function (DGF) was defined as the need for dialysis within the first week after transplanta-
tion. DGF and ARE data were retrospectively retrieved from clinical records up until the first
year after grafting. To estimate death-censored allograft survival, patients were followed up
until the earliest of graft loss (defined as the absence of kidney function, occurring any time
after transplantation due to irreversible graft injury requiring chronic dialysis and/or re-trans-
plantation), death with a functioning graft or December 31, 2013.
Renal function was assessed by estimating the glomerular filtration rate (eGFR) from serum
creatinine using the Modification of Diet in Renal Disease (MDRD) formula [21]: eGFR (ml
min-1 1.73 m-2) = 186 x (Serum Creatinin-1.154 x Age-0.203) x (1.212 if Black) x (0.742 if Female).
Several studies have reported that among renal transplanted patients the MDRD values show a
better correlation with the true filtration rate in comparison with other renal function esti-
mates, e.g. raw serum creatinine or the Cockcroft-Gault formula [22].
Ethics Statement
All participants gave oral and written consent for their participation. The study was approved
by the Ethics Committee of the Infanta Cristina Hospital (Reference No. 18002657), and was
conducted in accordance with the Declaration of Helsinki and its subsequent revisions.
Genotype analysis
Genomic DNA was isolated by using a QIAamp DNA Blood Kit (Qiagen, Hilden, Germany)
from either whole blood samples, in the case of the recipients, or from previously frozen lym-
phocytes obtained from donors. All three EPHX2 SNPs (Table 1) were identified by real-time
PCR using TaqMan SNP Genotype Assays from Life Technologies (Rockville, MD, USA).
For the haplotype study, the SNPstats platform [23] was utilized to provide linkage disequi-
librium data and to estimate the effect of haplotypes on the risk for acute rejection by linear
regression modelling; regression parameters pertained to the log odds ratios adjusted by the
same clinical and demographic variables used in the single-SNP study (see below). Frequency
threshold for rare haplotypes was set at 0.01.
Statistical analyses
Fisher’s exact or Pearson’s X2 test were used for the univariate analysis of the associations
between categorical data (i.e. genotypes vs. clinical events). In order to compare quantitative
EPHX2 Polymorphisms in Renal Transplant
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variables (e.g. eGFR) between the different genotype groups, T-student or ANOVA tests were
used depending on the number of groups considered. Multivariate regression analysis was per-
formed to collectively assess the impact of both genetic and non-genetic parameters. Analyses
were adjusted for demographic and clinical covariates according to statistical significance in uni-
variate studies and/or clinical criteria described elsewhere [18,24]. Variables included were age of
donors and recipients, type of immunosuppression, presence of DGF, cold ischemia time> 24
hours, number of HLAmismatches 3, and peak cytotoxic PRA50%. The age of both donors
and recipients was transformed into categorical variables using the median values as cut-off
points (49 and 51 years for recipients and donors, respectively). Association of the three EPHX2
SNPs with death-censored allograft survival was analyzed by Cox regression analyses.
SNPstats was used to determine the adequate model of inheritance (additive, dominant or
recessive). Statistical analysis was performed using the Statistical Package for the Social Sci-
ences (SPSS) version 15.0 for Windows (SPSS Inc., Chicago, Ill. USA). In all instances differ-
ences were considered to be significant when p values were lower than 0.05.
Results
Demographic and clinical characteristics of the 259 transplant recipients analyzed in the study
are described in Table 2. The most common primary kidney disease was glomerulonephritis
(42.1%), followed by chronic interstitial nephritis (11.2%) and polycystic kidney disease
(8.7%). Several other conditions accounted for 14.2% of cases. In 23.8% of the patients the spe-
cific condition could not be determined. Induction therapy was implemented in 53 subjects
(20.5%) with antibodies against interleukin-2 receptor (basiliximab) and in 9 patients (3.5%)
with thymoglobulin.
Genotype and minor allele frequencies, both in donors and recipients, are shown in Table 3.
Allele frequencies in the population of study were all in Hardy-Weinberg equilibrium (p-
values> 0.05).
Association of genetic polymorphisms in donors and recipients with graft
function and survival
The eGFR in the recipients increased from 33.29 ± 14.07 to 44.02 ± 14.83 in the one-year fol-
low-up period (p = 9.3 e-22). Amongst the SNPs analyzed, we found that subjects who carried
the rs1042032 GG genotype displayed worse estimated renal function at all four time-points
considered, compared to carriers of the wild type A-allele (Fig 1). Differences reached statistical
significance at the end of the one-year follow-up (38.15 ± 15.57 vs. 45.99 ± 16.05 for GG and
AA/AG respectively; p = 0.04). In a similar manner, the same genotype was also associated to
Table 1. Location, consequence and context sequence of the three EPHX2 SNPs analyzed in this study, as provided by the manufacturer of the
TaqMan SNP genotyping assays (Life Technologies, Maryland, USA).
SNP Transition Aminoacid
change
Location Context sequence [VIC/FAM]
rs41507953 A/G K55R Chr.8: 27358505 on NCBI
Build 37
GAGGGTGCCACTACCCGGCTTATGA[A/G]
AGGAGAGATCACACTTTCCCAGGTG
rs751141 A/G R287Q Chr.8: 27373865 on NCBI
Build 37
CCTGCTCTGGCCCAGGCAGGTTACC[A/G]
GGTCCTAGCTATGGACATGAAAGGC
rs1042032 A/G None (3’-UTR) Chr.8: 27402074 on NCBI
Build 37
TGTGCCCACGCTCAGCAGGTGTGCC[A/G]
TCCTTCCACCTGCTGGGGCACCATT
UTR, untranslated region.
doi:10.1371/journal.pone.0133563.t001
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higher serum creatinine values throughout the study (Fig 2) and again the difference was sig-
nificant twelve months after grafting (1.57 ± 0.58 vs. 1.30 ± 0.47 g/dL for GG and AA/AG
respectively; p = 0.02). In contrast, neither the rs1042032 GG genotype in the donor nor the
other two SNPs analyzed showed a relevant effect on the measured renal function (S1 and S2
Table 2. Clinical and demographic parameters of the study population. Four time-points within a one-year follow-up were considered.
Time-point One week One month 5 months One year
Creatinine serum concentration (mg/dL) 2.48 ± 2.07 1.69 ± 0.93 1.49 ± 0.72 1.38 ± 0.62
eGFR (ml min-1 1.73 m-2) 33.29 ± 14.10 36.90 ± 13.73 41.60 ± 13.98 44.02 ± 14.83
Recipients on tacrolimus 208 (80.3)
Dose (mg/kg) 0.14 ± 0.07 0.11 ± 0.06 0.08 ± 0.04 0.06 ± 0.06
Dose-normalized Tac blood concentration (ng/ml per mg/day
per kg)
111.0 ± 80.1 121.1 ± 66.7 162.5± 77.0 176.3 ± 110.1
Recipients on cyclosporine 51 (19.7)
Dose (mg/kg) 8.0 ± 1.9 6.3 ± 1.6 4.5 ±1.7 3.5 ± 1.1
Dose-normalized CsA blood concentration (ng/ml per mg/day
per kg)
42.32 ± 20.13 53.91 ± 22.48 51.04 ± 17.96 50.16 ± 18.98
Recipients sex (male/female) 158 (61.0) / 101 (39.0)
Recipients age (years) 48.18 ± 14.31
Type of dialysis (hemodialysis/peritoneal) 174 (67.2)/85 (32.8)
Duration of dialysis before transplantation (months) 38.16 ± 30.09
Donor age (years) 47.63 ± 17.51
Number of transplants (ﬁrst/second/third) 246 (95.0)/11 (4.2)/1
(0.8)
Cold ischemia time (hours) 16.22 ± 5.01
Peak cytotoxic PRA  50% 20 (7.72)
HLA mismatch
0–2 69 (26.64)
3–4 162 (62.54)
5–6 28 (10.81)
Data are shown as number (percentage) or mean ± standard deviation.
doi:10.1371/journal.pone.0133563.t002
Table 3. Genotypic and allelic frequencies in donors and renal transplant recipients.
Recipients Donors
Polymorphism N % N % MAF
EPHX2 K55R, rs41507953 KK 215 83.0 133 72.7 0.114
KR 40 15.4 47 25.7
RR 4 1.5 3 1.6
EPHX2 R287Q, rs751141 RR 223 86.1 153 83.6 0.076
RQ 36 13.9 29 15.8
QQ 0 0.0 1 0.5
EPHX2 3’UTR A>G, rs1042032 AA 153 59.1 81 44.3 0.273
AG 85 32.8 90 49.2
GG 21 8.1 12 6.6
N, number of subjects; MAF, minor allele frequency.
doi:10.1371/journal.pone.0133563.t003
EPHX2 Polymorphisms in Renal Transplant
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Tables show mean eGFR and serum creatinine values for the rs41507953 and rs751141
polymorphisms).
The mean follow-up time for the graft survival study was 114.65 ± 60.07 months. There
were no differences with regard to death-censored allograft survival when patients were strati-
fied according to their genotype or that of their donors. Hazard ratios with 95% confidence
intervals obtained by Cox regression analyses are shown in S3 Table.
Fig 1. Effect of the EPHX2 3’ UTR A/G polymorphism (rs1042032) of the recipient on the estimated glomerular filtration rate throughout the one-
year follow-up. *p<0.05 vs. AA/AG group.
doi:10.1371/journal.pone.0133563.g001
Fig 2. Effect of the EPHX2 3’ UTR A/G polymorphism (rs1042032) of the recipient on serum creatinine concentrations throughout the one-year
follow-up. *p<0.05 vs. AA/AG group.
doi:10.1371/journal.pone.0133563.g002
EPHX2 Polymorphisms in Renal Transplant
PLOS ONE | DOI:10.1371/journal.pone.0133563 July 31, 2015 6 / 12
Association of genetic polymorphisms in donors and recipients with
acute rejection
Thirty-one patients (11.96%) experienced ARE according to the diagnostic criteria described in
Methods. The incidence of acute rejection was significantly more frequent in carriers of the
rs1042032 GG genotype, compared to subjects with the wildtype AA genotype (Table 4). In
addition, a borderline association was observed for the GG genotype of the donor [OR = 4.80
(0.96–26.54)]. When the participants were analyzed using a recessive model (rs1042032 GG vs.
AA/AG) the significance level of the association further increased [OR = 6.34 (1.35–29.90),
p = 0.015 and OR = 5.53 (1.10–27.80), p = 0.042 for recipient and donor genotypes, respec-
tively]. In the case of the recipients’ genotype, the association remained significant after correc-
tion for multiple testing.
In order to determine the relative weight of the donor vs. recipient rs1042032 GG genotype
in the risk for ARE, we created a statistical model that included both genotypes along with sig-
nificant demographic and clinical covariates described in methods. The results shows that the
significance of the donor rs1042032 GG genotype decreased slightly [OR = 5.84 (0.82–37.88),
p = 0.078]; in contrast, the OR value for the recipient’s GG genotype increased up to an OR of
8.28 (1.21–74.27) with a p-value of 0.031. This genotype presented the highest regression coef-
ficient of all variables tested (B = 2.11). Amongst non-genetic factors, the impact of DGF,
which was present in 29.1% of the patients and had shown a strong association with ARE in
univariate analysis [OR = 9.66 (3.68–25.35); p< 0.001] decreased to a borderline association
[OR = 2.72 (0.94–11.66)]. DGF occurrence was not significantly associated with any of the
studied SNPs. The model explained 36.3% of the variability in the sample.
Finally, we tested whether there was any modification of ARE risk when the three EPHX2
loci were analyzed combined. Linkage disequilibrium data (D’, r2) were 0.99, 0.008 for
rs41507953/rs751141; 0.78, 0.186 for rs41507953/rs1042032 and 0.92, 0.196 for rs751141/
rs1042032 in recipients and 0.99, 0.016; 0.75, 0.109 and 0.95, 0.307 for the same SNP pairs in
donors. Table 5 shows the different haplotypes identified and their association with the risk for
ARE. Haplotype distribution was not different between donors and recipients (Chi-square
p> 0.05). Only haplotype 2 in the recipient (rs41507953 A / rs751141 A/ rs1042032 G) dis-
played a statistical trend towards higher risk of ARE [OR = 2.28 (0.92–5.67), p = 0.08]. The
analyses were adjusted by the same variables as in the single-SNP study.
Table 4. Odds ratios (OR) with 95% confidence intervals (CI) for the association of EPHX2 SNPs with
acute rejection in renal transplant recipients.
Recipients Donors
Polymorphism OR (CI) p OR (CI) p
EPHX2 K55R KK Ref. 0.83 Ref. 0.43
KR 1.23 (0.35–4.28) 1.53 (0.49–4.79)
RR NC 6.61 (0.28–156.51)
EPHX2 R287Q RR Ref. 0.38 Ref. 0.48
RQ 1.93 (0.46–8.01) 1.77 (0.35–7.24)
QQ NC NC
EPHX2 3’UTR A>G AA Ref. 0.04 Ref. 0.11
AG 0.64 (0.15–2.67) 0.76 (0.25–2.33)
GG 5.45 (1.09–27.21) 4.80 (0.96–26.54)
NC, non-calculable.
doi:10.1371/journal.pone.0133563.t004
EPHX2 Polymorphisms in Renal Transplant
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Discussion
Some ten years ago, two studies revealed that a CYP3A5 allele was able to predict tacrolimus
concentration-to-dose ratios in renal transplant recipients [25,26]. This finding prompted the
publication of a great number of reports aimed to determine an association between genetic
variants and meaningful clinical parameters in renal transplantation. The vast majority of
these studies have focused on the variability in the CYP3A and ABCB1 genes, which are respon-
sible for the metabolism and transport of anticalcineurin inhibitors [27,28]. However, it is
somewhat surprising the lack of attention that has attracted the role of EPHX2 variants in the
field of renal transplantation. It is even more so when EETs, the substrates for the EPHX2-
encoded sEH, are vital components of the renal and vascular response to injury such as that
produced in ischemia-reperfusion [2,29]. Indeed, AR9281 and GSK2256294 are new sEH
inhibitors that are being tested in clinical trials to assess their efficacy and safety for the treat-
ment of hypertension and other cardiovascular diseases [30,31].
In the present paper we have evaluated the impact of common genetic variability in the gene
coding for sEH, the enzyme responsible for EETs degradation in the kidney. We observed that
the GG genotype of the rs1042032 A/G SNP was associated with lower eGFR and higher serum
creatinine values, particularly late in the study period. Only one previous study by Lee et al. [16]
has analyzed the clinical role of this SNP in renal transplantation. The authors did not find a rel-
evant impact of the GG genotype on their patients’ renal function, quite the opposite; they
reported an association of the wild type AA genotype with allograft dysfunction. In contrast
with recent evidence (see below) this study assumed that the SNP resulted in reduced enzyme
activity, although the authors failed to confirm this in vitro. Some facts could also explain the
discrepancy with our results. First, the patients in the study by Lee et al. were Asian who dis-
played a much higher MAF for the SNP (0.445 vs. 0.273 in our patients). Second, their study set-
ting was living-donor transplantation, which generally means lower rates of graft dysfunction
and acute rejection [32]; and last but not least, the study by Lee et al. only detected an associa-
tion of the AA genotype with worse renal function when participants were stratified into two
groups (High/Low eGFR), because when raw numbers were considered eGFR values were not
significantly different. In fact, it is interesting that, in line with our results, serum creatinine val-
ues were higher in carriers of the variant G-allele [16]. In any case, our findings should be
Table 5. Effect of EPHX2 haplotypes both in donors and recipients on the risk for acute rejection.
Haplotype Frequency rs41507953 rs751141 rs1042032 OR (CI) p
Recipients
*1 0.732 wt wt wt Reference
*2 0.114 wt wt M 2.28 (0.92–5.67) 0.08
*3 0.082 M wt M 0.24 (0.01–4.14) 0.33
*4 0.065 wt M M 3.09 (0.76–12.52) 0.12
*5 <0.01 M wt wt -
Donors
*1 0.662 wt wt wt Reference
*2 0.116 wt wt M 0.94 (0.26–3.37) 0.93
*3 0.077 M wt M 1.96 (0.53–7.29) 0.32
*4 0.137 wt M M 2.21 (0.81–6.00) 0.12
*5 <0.01 M wt wt -
wt, wild type allele. M, variant allele.
doi:10.1371/journal.pone.0133563.t005
EPHX2 Polymorphisms in Renal Transplant
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interpreted cautiously, given the existence of contradictory results. On the other hand, we did
not observe a significant effect of the rs1042032 SNP on long-term graft survival. It is tempting
to speculate that, in the long term, the protective effect of EETs [2,14] may be eclipsed by other
factors such as chronic exposure to medication or the occurrence of infections.
The most relevant finding of this study was the fact that the rs1042032 GG genotype, both
in donors and recipients, was associated with a higher risk of ARE after adjusting for demo-
graphic and clinical covariates. Interestingly, the only two recipients that carried the GG geno-
type and also received a kidney from a GG donor experienced ARE. The most likely
explanation for this observation must be an increase of enzymatic activity produced by the
SNP, because that would imply a faster rate of EETs degradation, subsequent endothelial dys-
function, increased blood pressure and, eventually, glomerular injury, as it has previously sug-
gested [2]. In line with this hypothesis, two recent studies have demonstrated that enhanced
activity of sEH increases the severity of the ischemia-reperfusion injury in the kidney [14] and
is also associated with more advanced endothelial dysfunction [33], which are common com-
plications in kidney transplantation [34]. Moreover, recent data available in the Genevar
(GENe Expression VARiation) database [35] at the Sanger Institute website (http://www.
sanger.ac.uk/resources/software/genevar) seem to confirm that this SNP is associated with
increased enzyme activity. Genevar charts show that subjects from different ethnicities carrying
the rs1042032 GG genotype, which we found to be related to increased risk of acute rejection
and worse renal function, display significantly higher expression of sEH (S1 Fig). This would
presumably lead to lower levels of EETs and, consequently, to a lower endogenous capacity of
counteracting damaging processes in the graft. Furthermore, an increased sEH activity could
also be the explanation for the borderline association with ARE observed with haplotype 2 in
the recipient, since this allele combination contained the aforementioned 1042032 G variant
and two wild type alleles in the other loci; an allele constellation that would presumably lead to
a faster rate of EETs degradation.
The statistical model proposed in the present work indicates that the EPHX2 genotype of
the recipient was more important to predict ARE than that of the donor, which underlines the
importance of vascular and/or inflammatory mechanisms at a systemic level. In line with this
finding, it was also the 1042032 GG genotype of the recipient, but not that of the donor, that
was associated with worse graft function. Indeed, along with kidney EETs concentrations,
decreased levels of vascular EETs have also been associated with renal diseases [2]. Future stud-
ies including circulating levels of EETs and, particularly, the actual expression of these com-
pounds in the graft may help elucidate this question.
In any case, the statistical model presented herein should be validated in larger cohorts and,
as such, has more of an academic than a clinical value. In this regard, a limitation of this work
was its relatively small sample size, which may have been particularly relevant for some wide,
although significant, confidence intervals. In addition, availability of genetic material from
deceased donors was incomplete, which was not unexpected as DNA was obtained from lym-
phocytes that in some cases had been frozen for years. Another limitation was the lack of data
on circulating levels of EETs (a parameter not available in a retrospective study) or on enzyme
expression in the graft, which could have been helpful to confirm the proposed hypotheses. In
this regard, protocol biopsies in subjects with stable graft function or in those with unambigu-
ous clinical data are not performed in our centers, and therefore there was not enough tissue
available as to carry out protein expression studies in this series of patients. This lack of histo-
logical confirmation for all acute rejection episodes may have also affected the reported inci-
dence of this complication. On the other hand, the fact that the donor genotype was available
greatly increased the significance of some findings, such as the aforementioned association
with acute rejection observed for the rs1042032 SNP of both donors and recipients.
EPHX2 Polymorphisms in Renal Transplant
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In conclusion, in a study designed with mechanism-linked, established polymorphisms, we
have shown for the first time to our knowledge, that genetic variability in the EETs-metabolizing
gene, EPHX2, may have a significant impact on the outcome of deceased-donor renal transplan-
tation. The explanation for this finding most likely implies the modulation of the levels of EETs,
with vasoactive and anti-inflammatories properties. The findings described in the present work
may be the first step in a new field of research on the role of genetic variants affecting EETs avail-
ability in renal transplant. Further work with larger, independent series of patients and/or addi-
tional genes involved in EETs synthesis is warranted to confirm the findings described herein.
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